Follicular development and hormone concentrations following recombinant FSH administration for anovulation associated with polycystic ovarian syndrome: prospective, randomized comparison between low-dose step-up and modified step-down regimens

2001 ◽  
Vol 16 (4) ◽  
pp. 652-656 ◽  
Author(s):  
Juan Balasch ◽  
Francisco Fábregues ◽  
Montserrat Creus ◽  
Bienvenido Puerto ◽  
Joana Peñarrubia ◽  
...  
Keyword(s):  
Low Dose ◽  
Polycystic Ovarian Syndrome ◽  
Follicular Development ◽  
Recombinant Fsh ◽  
Step Down ◽  
Dose Step ◽  
Ovarian Syndrome

scholarly journals Management Infertility by Hormones Replacement Therapy in Women with Polycystic Ovarian Syndrome

2020 ◽  
Vol 10 (1) ◽  
pp. 170-174
Author(s):  
Sardar Q. Umer ◽  
Tariq W. Sadeq
Keyword(s):  
Low Dose ◽  
Polycystic Ovarian Syndrome ◽  
Polycystic Ovary ◽  
Follicle Stimulating Hormone ◽  
Serum Testosterone ◽  
Recombinant Fsh ◽  
Short And Long Term ◽  
Ovarian Syndrome ◽  
Stimulating Hormone

Polycystic ovary syndrome (PCOS) is an endocrine-metabolic disorder characterized by multiple hormonal imbalances; the clinical presentation dominated by manifestations of hyperandrogenism, which generates short- and long-term consequences on female health sterility, infertility is one of the most alarming associated morbidities. Forty women (28.9 ± 0.8 years old) with polycystic ovarian syndrome had infertility and there were enrolled in these clinical trials and randomly allocated into two groups. Group one and Group two were given treated infertility drugs (Clomid 5 mg for 5 days) and recombinant follicle-stimulating hormone (rFSH) 75 IU for long and short duration to get pregnant. Serum testosterone, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) of both groups were measured when women diagnosed as PCOS. The results showed that women which treated by low-dose recombinant FSH 75 IU for 3 days consequently (Group one) have significant decreased LH, while progesterone and FSH significantly increased after treated by hormone therapy P ≥ 0.05 while after treatment with recombinant FSH IU for 5 days (Group two), the result showed non-significant effect as compared with the first group. Concluded: Increase pregnant rate and decrease over stimulation syndrome among infertile women associated with polycystic overian syndrome, when treated with applicated low dose and short term by rFSH hormone.

Ovulation induction by step-down administration of purified urinary follicle-stimulating hormone in patients with polycystic ovarian syndrome

1991 ◽  
Vol 55 (6) ◽  
pp. 1195-1196 ◽  
Author(s):  
Hideki Mizunuma ◽  
Takeshi Takagi ◽  
Kiyohiko Yamada ◽  
Kazumichi Andoh ◽  
Yosito Ibuki ◽  
...  
Keyword(s):  
Ovulation Induction ◽  
Polycystic Ovarian Syndrome ◽  
Follicle Stimulating Hormone ◽  
Step Down ◽  
Ovarian Syndrome ◽  
Stimulating Hormone

Low-Dose Gonadotropin Therapy in Polycystic Ovarian Syndrome

1993 ◽  
Vol 687 (1 Intraovarian) ◽  
pp. 301-304 ◽  
Author(s):  
S. FRANKS ◽  
D. HAMILTON-FAIRLEY ◽  
M. SAGLE ◽  
D. POLSON ◽  
D. KIDDY ◽  
...  
Keyword(s):  
Low Dose ◽  
Polycystic Ovarian Syndrome ◽  
Ovarian Syndrome ◽  
Gonadotropin Therapy

scholarly journals Hyperandrogenism in polycystic ovarian syndrome and role of CYP gene variants: a review

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Sairish Ashraf ◽  
Mudasar Nabi ◽  
Shayaq ul Abeer Rasool ◽  
Fouzia Rashid ◽  
Shajrul Amin
Keyword(s):  
Polycystic Ovarian Syndrome ◽  
Polycystic Ovary ◽  
Follicular Development ◽  
Pulse Frequency ◽  
Ovary Syndrome ◽  
Ovarian Morphology ◽  
Genetic And Environmental Factors ◽  
Hallmark Feature ◽  
Ovarian Syndrome

Abstract Background Polycystic ovary syndrome (PCOS) is a multifactorial endocrine disorder characterized by anovulation, hyperandrogenism, and polycystic ovarian morphology. The pathophysiology of PCOS is not clear; however, disturbance in hypothalamic-pituitary-ovarian axis and abnormal steroidogenesis along with genetic and environmental factors act as main contributors to this disorder. Main text Hyperandrogenism, the hallmark feature of PCOS, is clinically manifested as hirsutism, acne, and alopecia. Excessive androgen production by ovaries as well as from adrenals contributes to hyperandrogenism. Abnormalities in the neuroendocrine system like increased pulse frequency of gonadotropin-releasing hormone, stimulating the pituitary for excessive production of luteinizing hormone than that of follicle-stimulating hormone is seen in PCOS women. Excess LH stimulates ovarian androgen production, whereas a relative deficit in FSH impairs follicular development. The imbalance in LH: FSH causes proliferation of ovarian theca cells leading to increased steroidogenesis, and ultimately leading to hyperandrogenism in PCOS women. Various genetic factors have been shown to be associated with abnormal steroidogenesis. CYP genes involved in steroidogenesis play an important role in androgen production and are considered as key players in hyperandrogenism in PCOS. Conclusion Polymorphisms in CYP genes can aggravate the hyperandrogenic phenotype in women with PCOS by either upregulating or downregulating their expression, thus increasing androgens further. However, this hypothesis needs to be validated by further studies.

Sign in / Sign up

Export Citation Format

Share Document